<DOC>
	<DOCNO>NCT01045018</DOCNO>
	<brief_summary>The objective bioequivalence study patient ulcerative colitis ( UC ) : - To establish therapeutic equivalence mesalamine delay release tablet ( MDRT ) Asacol Delayed Release Tablets 2.4 g per day ( 800 mg three time daily ) - To evaluate safety MDRT 2.4 g per day ( 800 mg three time daily ) compare placebo .</brief_summary>
	<brief_title>A BE Study Comparing Mesalamine 400 mg ASACOL® 400 mg Patients With Mild To Moderately Active Ulcerative Colitis</brief_title>
	<detailed_description>This multi-center , randomize , parallel-groups comparison two mesalamine product treatment ulcerative colitis . Patients randomly assign optimized 2:2:1 ratio MDRT 2.4 g/day , Asacol 2.4 g/day , placebo . The study partially blind due difficulty associate create placebo match MDRT Asacol ; placebo match MDRT formulation . Placebo group serve control parallel group comparison MDRT Asacol . Patients treat 6 week randomization follow Day 56 , consider sufficient length accommodate safety issue assess efficacy base upon prior clinical trial mesalamine patient mild moderate active UC describe introduction</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Adults newly diagnose ulcerative colitis relapse follow prior treatment meet follow criterion eligible participation study : 1 . IRB approve consent form sign dated prior studyrelated activity 2 . Male , female , undergone sterilization ( hysterectomy bilateral tubal ligation ) , postmenopausal ( define 1 year without menses ) negative pregnancy test screening , heterosexually active , use agree continue use : doublebarrier method contraception ( condom spermicide ) , oral patch contraceptive , intrauterine device , monogamous relationship partner undergone vasectomy . 3 . 18 year age old 4 . Newly diagnose ulcerative colitis relapse follow prior treatment 5 . Patient take &gt; 1.6 g/day mesalamine equivalent 14 day prior randomization 6 . Disease extend ≥ 15 cm anal verge screen sigmoidoscopy colonoscopy confirm biopsy 7 . Mild moderate ulcerative colitis , define Disease Activity Index ( DAI ) score 4 9 , inclusive , study entry , PGA 1 2 mucosal appearance ( determine endoscopy exam ) score 1 2 ( mild/moderate ) 8 . Able willing keep daily diary study 1 . Treatment topical rectal , oral , intravenous ( IV ) corticosteroid within 30 day screen immunosuppressive ( e.g . azathioprine , 6mercaptopurine ) within 90 day immediately precede Screening 2 . Use rectal administer aminosalicylates within 7 day randomization 3 . Patient take great 1.6 g/day mesalamine equivalent within 14 day randomization 4 . Crohn 's disease , ischemic colitis , disease bacterial origin 5 . Known allergy hypersensitivity aspirin salicylate compound 6 . History laboratory result show significant hepatic renal disease significant medical condition opinion investigator preclude participation study base efficacy/safety assessment 7 . History cancer basal cell carcinoma within five year immediately precede study entry 8 . In relapse &gt; 3 week prior screen visit 9 . Proctitis 15 cm anal verge 10 . History current gastrointestinal bleeding bloody stool associate ulcerative colitis 11 . History bleed disorder 12 . Active peptic ulcer disease , history gastrointestinal obstruction include severe constipation , anatomic abnormality GI tract 13 . Previous colonic surgery 14 . History alcohol substance abuse within year immediately precede anticipate study entry 15 . HIV positive 16 . &gt; 6 bloody stool per day 17 . Positive stool culture ovum and/or parasite , enteric pathogen include Salmonella , Shigella , Yersinia , Campylobacter , positive stool assay C. difficile toxin 18 . Pregnant breast feed 19 . Used investigational drug 30 day prior randomization 20 . BUN serum creatinine level 1.5 time upper limit normal ( ULN ) liver enzyme level &gt; 2 time ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>colitis</keyword>
	<keyword>ulcerative</keyword>
	<keyword>ulcerative colitis</keyword>
</DOC>